Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 1/20 | 0.41 |
| ▸ | LYPLA1 | O75608 | 2/20 | 0.39 |
| ▸ | LYPLA2 | O95372 | 2/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | PLA2G6 | O60733 | 2/20 | 0.33 |
| ▸ | ABHD16A | O95870 | 1/20 | 0.33 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16201804 | 0.83 | FASN (0.40) | FASNLYPLA1LYPLA2SIRT2PLA2G6 | |
| SCHEMBL16201812 | 0.76 | FASN (0.69) | FASNLYPLA1LYPLA2PLA2G6ABHD16A | |
| SCHEMBL31751418 | 0.66 | KIF11 (0.41) | SIRT2KIF11 | |
| SCHEMBL17791489 | 0.66 | FFAR1 (0.49) | KIF11 | |
| SCHEMBL18969775 | 0.65 | KIF11 (0.40) | SIRT2KIF11DUSP3 | |
| SCHEMBL15012514 | 0.64 | KIF11 (0.40) | SIRT2ABCB1KIF11DUSP3 | |
| SCHEMBL17600538 | 0.63 | KIF11 (0.39) | ABCB1KIF11 | |
| SCHEMBL18021017 | 0.62 | KIF11 (0.38) | SIRT2KIF11 | |
| SCHEMBL2535263 | 0.62 | KIF11 (0.42) | SIRT2ABCB1KIF11 | |
| SCHEMBL16201787 | 0.62 | KIF11 (0.35) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140323457-A1 | BETA-O/S/N FATTY ACID BASED COMPOUNDS AS ANTIBACTERIAL AND ANTIPROTOZOAL AGENTS | Technische Universität München (DE) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323457-A1 | BETA-O/S/N FATTY ACID BASED COMPOUNDS AS ANTIBACTERIAL AND ANTIPROTOZOAL AGENTS | FASN, DEGS1, EBP | FASN 1/4885LYPLA1 1206/4885LYPLA2 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.